603669 Stock Overview
Lionco Pharmaceutical Group Co., Ltd., together with its subsidiaries, researches, develops, produces, and sells pharmaceuticals in China. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Lionco Pharmaceutical Group Co.,Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CN¥5.56 |
| 52 Week High | CN¥9.54 |
| 52 Week Low | CN¥2.94 |
| Beta | 0.22 |
| 1 Month Change | -12.72% |
| 3 Month Change | 20.87% |
| 1 Year Change | 17.30% |
| 3 Year Change | -33.65% |
| 5 Year Change | 0.31% |
| Change since IPO | -9.46% |
Recent News & Updates
Lionco Pharmaceutical Group Co.,Ltd. (SHSE:603669) May Have Run Too Fast Too Soon With Recent 28% Price Plummet
Jan 02
Subdued Growth No Barrier To Lionco Pharmaceutical Group Co.,Ltd. (SHSE:603669) With Shares Advancing 30%
Nov 06Lionco Pharmaceutical GroupLtd (SHSE:603669) Has Debt But No Earnings; Should You Worry?
Oct 29Recent updates
Lionco Pharmaceutical Group Co.,Ltd. (SHSE:603669) May Have Run Too Fast Too Soon With Recent 28% Price Plummet
Jan 02Subdued Growth No Barrier To Lionco Pharmaceutical Group Co.,Ltd. (SHSE:603669) With Shares Advancing 30%
Nov 06Lionco Pharmaceutical GroupLtd (SHSE:603669) Has Debt But No Earnings; Should You Worry?
Oct 29Lionco Pharmaceutical Group Co.,Ltd. (SHSE:603669) Stock Rockets 26% As Investors Are Less Pessimistic Than Expected
May 10There's Reason For Concern Over Lionco Pharmaceutical Group Co.,Ltd.'s (SHSE:603669) Massive 28% Price Jump
Mar 12Shareholder Returns
| 603669 | CN Pharmaceuticals | CN Market | |
|---|---|---|---|
| 7D | 3.7% | 3.5% | 4.2% |
| 1Y | 17.3% | 2.8% | 16.1% |
Return vs Industry: 603669 exceeded the CN Pharmaceuticals industry which returned 2.8% over the past year.
Return vs Market: 603669 exceeded the CN Market which returned 16.1% over the past year.
Price Volatility
| 603669 volatility | |
|---|---|
| 603669 Average Weekly Movement | 10.1% |
| Pharmaceuticals Industry Average Movement | 5.6% |
| Market Average Movement | 7.0% |
| 10% most volatile stocks in CN Market | 11.0% |
| 10% least volatile stocks in CN Market | 4.1% |
Stable Share Price: 603669's share price has been volatile over the past 3 months compared to the CN market.
Volatility Over Time: 603669's weekly volatility (10%) has been stable over the past year, but is still higher than 75% of CN stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2003 | 475 | Ling Ping Tao | www.lingkang.com.cn |
Lionco Pharmaceutical Group Co., Ltd., together with its subsidiaries, researches, develops, produces, and sells pharmaceuticals in China. The company offers nutrition, antimicrobial, antiviral, digestion, cardiovascular, detoxification, anti-tumor, and other products. Lionco Pharmaceutical Group Co., Ltd.
Lionco Pharmaceutical Group Co.,Ltd. Fundamentals Summary
| 603669 fundamental statistics | |
|---|---|
| Market cap | CN¥3.91b |
| Earnings (TTM) | -CN¥101.80m |
| Revenue (TTM) | CN¥277.20m |
14.1x
P/S Ratio-38.4x
P/E RatioIs 603669 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 603669 income statement (TTM) | |
|---|---|
| Revenue | CN¥277.20m |
| Cost of Revenue | CN¥162.18m |
| Gross Profit | CN¥115.02m |
| Other Expenses | CN¥216.82m |
| Earnings | -CN¥101.80m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
Apr 19, 2025
| Earnings per share (EPS) | -0.14 |
| Gross Margin | 41.49% |
| Net Profit Margin | -36.73% |
| Debt/Equity Ratio | 30.3% |
How did 603669 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/21 21:03 |
| End of Day Share Price | 2025/01/21 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Lionco Pharmaceutical Group Co.,Ltd. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|